Monitoring real-life utilization of pembrolizumab in advanced melanoma using the Portuguese National Cancer Registry.

Objectives: To evaluate the effectiveness and safety of pembrolizumab use in advanced melanoma in a real-life context; and to explore the existence of an efficacy-effectiveness gap, comparing registry data with the reference clinical trial.

Methods: This study followed the guidelines for good pharmacoepidemology practice. An ambispective cohort was constituted, initiating the observation upon drug approval (17/07/2015) and following exposed patients until death or cut-off date (15/11/2019).

Real-world effectiveness of pembrolizumab in previously treated non-small cell lung cancer: A population-based cohort study.

Purpose: Immunotherapy is promising for lung cancer treatment, although at significant financial impact. The aim of this study was to evaluate the effectiveness and the efficacy-effectiveness gap of pembrolizumab in previously treated non-small cell lung cancer (NSCLC).

Methods: A population-based ambispective cohort study was conducted.